Payment overview · 2025
General Payments
$3,877.53
232 reported records · 27 companies
Healthcare provider profile · identity verified
Mark Stephen Rosenberg, DO
Allopathic & Osteopathic Physicians|Family Medicine · STERLING HEIGHTS, MI · NPI 1184601510
Verified facts
What the public records show
CMS Open Payments records show Mark Stephen Rosenberg, DO received $3,877.53 in general payments during 2025 across 232 reported records.
ABBVIE INC. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $440.82 | 11.4% | 34 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $400.67 | 10.3% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $372.91 | 9.6% | 26 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $320.87 | 8.3% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $312.27 | 8.1% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $227.63 | 5.9% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $190.41 | 4.9% | 15 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $167.92 | 4.3% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $164.36 | 4.2% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $161.04 | 4.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $143.41 | 3.7% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $128.16 | 3.3% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $110.79 | 2.9% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $110.67 | 2.9% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.50 | 2.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $82.47 | 2.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.13 | 2.1% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.14 | 1.7% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$60.26 | 1.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.48 | 1.5% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $36.08 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.26 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.31 | 0.8% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.01 | 0.7% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $24.62 | 0.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.32 | 0.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.02 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,877.53 | 232 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $278.56 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $250.46 | 23 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $245.69 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $245.69 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $237.86 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $227.63 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $216.47 | 13 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $190.41 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $190.36 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $190.36 | 11 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $171.27 | 9 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $171.27 | 9 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $171.27 | 9 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $167.92 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $164.36 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $149.60 | 11 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $128.16 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.16 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.22 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.98 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.98 | 9 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $114.77 | 7 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $110.79 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $110.67 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $109.93 | 5 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $97.16 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $92.68 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $82.47 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $82.13 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.14 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $63.88 | 7 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $60.26 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.48 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.92 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $36.08 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.31 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $27.01 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $17.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 78 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 73 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
64 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
78 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 396 | 139 |
| Ezetimibe | Ezetimibe | 320 | 100 |
| Spironolactone | Spironolactone | 304 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 293 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 75 |
| Losartan Potassium | Losartan Potassium | 222 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 221 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 61 |
| Omeprazole | Omeprazole | 155 | 59 |
| Jardiance | Empagliflozin | 139 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 54 |
| Enalapril Maleate | Enalapril Maleate | 114 | 41 |
| Metformin Hcl | Metformin Hcl | 105 | 36 |
| Gabapentin | Gabapentin | 100 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 27 |
| Methylprednisolone | Methylprednisolone | 86 | 65 |
| Alprazolam | Alprazolam | 84 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 31 |
| Tramadol Hcl | Tramadol Hcl | 80 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 25 |
| Repatha Sureclick | Evolocumab | 79 | 23 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 78 | 78 |
| Pregabalin | Pregabalin | 76 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 26 |
| Eliquis | Apixaban | 73 | 19 |
| Carvedilol | Carvedilol | 71 | 20 |
| Lisinopril | Lisinopril | 71 | 28 |
| Trazodone Hcl | Trazodone Hcl | 71 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 19 |
| Ozempic | Semaglutide | 65 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 64 | 50 |
| Farxiga | Dapagliflozin Propanediol | 62 | 20 |
| Trulicity | Dulaglutide | 59 | 13 |
| Glipizide Er | Glipizide | 58 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 15 |
| Furosemide | Furosemide | 54 | 25 |
| Mounjaro | Tirzepatide | 54 | 16 |
| Diazepam | Diazepam | 53 | 18 |
| Ibuprofen | Ibuprofen | 52 | 20 |
| Folic Acid | Folic Acid | 49 | 18 |
| Xarelto | Rivaroxaban | 46 | 14 |
| Famotidine | Famotidine | 45 | 20 |
| Meloxicam | Meloxicam | 44 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 17 |
| Potassium Chloride | Potassium Chloride | 42 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 18 |
| Myrbetriq | Mirabegron | 40 | 13 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 14 |
| Alendronate Sodium | Alendronate Sodium | 37 | 15 |
| Cephalexin | Cephalexin | 37 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 14 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Indapamide | Indapamide | 30 | 12 |
| Invokana | Canagliflozin | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Meclizine Hcl | Meclizine Hcl | 27 | 16 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Procto-Med Hc | Hydrocortisone | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Prednisone | Prednisone | 21 | 16 |
| Cilostazol | Cilostazol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 11 |
| Temazepam | Temazepam | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 11 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,877.53 · 232 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CHARTIS CATHETER, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, FANAPT, FARXIGA, INCEPTIV, INJECTAFER, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, TZIELD, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error